| |
|
 |
| Home/About
Us /Press
Releases |
|
Global
health leaders meet in Philadelphia to praise
"DE-ESCALATION THERAPY
Hospital-acquired pneumonia
focus of Merck Sharp & Dohme symposium
"De-Escalation Therapy,"™
the global campaign of Merck Sharp & Dohme (MSD)
to decrease mortality associated with life-threatening
infections in the intensive care unit such as hospital-acquired
pneumonia, was the subject of a one-day forum held
in Philadelphia, Pennsylvania, U.S.A. recently.
The cornerstone of the worldwide strategy surrounds
imipenem/cilastatin sodium, a broad-spectrum beta-lactam
antibiotic that overcomes resistance mechanisms
of the most prevalent bacteria found in hospitals.
The antibacterial spectrum of imipenem/cilastatin
sodium is broader than most antibiotic studied and
includes virtually all clinically significant pathogens.
Imipinem/cilastatin sodium has 16 years of clinical
experience and has been successfully used to treat
more than 20 million patients in more than 100 countries
since its inception in 1985. It has proved to be
effective in the treatment of hospital-acquired
infections and is highly effective in addressing
moderate-to-severe bacterial infections.
Intensive care unit physicians are concerned
about the growing incidence of serious infections,
such as hospital-acquired pneumonia. Even more
worrisome is the developing resistance to the
antibiotics that treat these infections. Indeed,
clinical studies reveal that hospital mortality
is significantly greater for patients receiving
initial inadequate antibiotic treatment than for
those receiving initial adequate microbial treatment
in the battle against nosocomial pneumonia. De-Escalation
Therapy, which focuses on initial adequate therapy
for serious, life-threatening infections, promotes
"hitting hard" with a broad-spectrum regimen that
ensures that all appropriate pathogens are covered.
|
Page
1
| 2
|
|
Print
Now!
